76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
N Nanosonics Ltd
N
Closed
SectorFinance
3.95 0.51
Overview
Share price change
24h
Min
3.82
Max
4.02
Income | 9.8M |
|---|---|
Sales | 94M |
P/E Sector Avg | 80.8 24.823 |
Profit margin | 10.428 |
Employees | 466 |
EBITDA | 9.8M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +31.67% upside |
Next Earnings | 26 Aug 2025 |
|---|
Market Cap | 182M 1.2B |
|---|---|
Previous open | 3.44 |
Previous close | 3.95 |
News Sentiment
By Acuity
52%
48%
447 / 536 Finance
Nanosonics Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Nanosonics Ltd Forecast
Price Target
By TipRanks
31.67% upside
12 Months Forecast
Average 5.069 AUD 31.67%
High 6 AUD
Low 4.05 AUD
Based on 3 Wall Street analysts offering 12 month price targets forNanosonics Ltd - Dist in the last 3 months.
Sentiment
By Acuity
447 / 536 Finance
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Nanosonics Ltd
Nanosonics Limited operates as an infection prevention company globally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.